| Product & AISEKIORTrustFinancialsOutlookGovernance |
Dear Shareholders,
2025 was a year in which AIMO sharpened its focus: we rebuilt our core product around artificial intelligence, completed a clean-up of our corporate structure, and laid the groundwork for a multi-year growth and innovation plan.
The AIMO app underwent a complete redesign and technical overhaul in 2025. The rebuild used AI-assisted development throughout, resulting in a materially more stable product: crash rates and customer-reported issues dropped drastically — a deliberate move to put AI at the center of how we build and run the product.
Management estimates that AI tooling has already more than tripled team productivity across product and engineering. We are extending this approach into sales and marketing, where AI-supported content creation and lead processes will be a key focus for 2026.
A new course concept built on our certified ZPP prevention-course framework launches in Q3 2026. Since insurer reimbursement is now tied to completed courses rather than registrations, broader course content is a direct lever on revenue.
AIMO is investing in proprietary AI research through SEKIOR (Sensor-Based Artificial Intelligence for the Objectification of Risk Assessment), a smartphone-only health and prevention scoring system. In a co-funded feasibility study (ZIM programme, BMWK, April 2025–April 2026), AIMO validated the technical, data-protection, and commercial feasibility. AIMO has applied for the follow-on R&D grant (SEKIOR I) with the University of Freiburg, DHBW Heilbronn, and PwC Strategy&; a BMWK funding decision is pending.
29,405 Active Users | 218,472 Completed Movement Scans | 349,509 Completed Training Sessions |
SEKIOR turns smartphone sensor data into a single, explainable health and risk score across four input dimensions. Validated against PwC’s Digital Patient Twin (~40 million anonymised PKV patient histories), reaching AUC ≥ 0.75 for predicting rehospitalisation risk — a credible, insurer-grade benchmark.
Simplified illustration of the SEKIOR scoring architecture.
B2C Subscription ≈ €100–120 / user / year Direct-to-consumer, in-app | B2B PKV Score Licensing ≈ €10–20 / insured / year Licensed to PKV insurers via API | SEKIOR II (Actuarial) Risk-adjusted pricing Follow-on project, post-SEKIOR I |
PwC Strategy&’s role is to scale the path to market: contributing the Digital Patient Twin benchmark and direct access to PKV decision-makers. AIMO and PwC have run pilot workshops with four large and two mid-sized PKV insurers. Management expects this to cut typical time-to-market from 2–3 years to approximately 12–18 months. The commercial basis is currently a Letter of Intent; the only funded PwC work package today is a €15,000 subcontract within the ZIM grant.
| Programme | Status | Funding |
|---|---|---|
| Feasibility study | Completed Apr 2026 | €87,472 ZIM grantof €124,953 total cost |
| SEKIOR I (main project) | Pending BMWK approval | ≈ €1.5m ZIM volume (consortium)≈ €297k AIMO co-financing / 24 mo. |
| Forschungszulage (R&D tax credit) | Applies from Jul 2026 | Additional non-dilutive R&D fundingAlso applicable to SEKIOR spend |
SEKIOR’s own business case sees revenue scaling over its first three years as B2B licensing ramps up (separate project-level estimate, not included in Group outlook below):
| 2026E | 2027E | 2028E |
|---|---|---|
| € 480k | € 850k | € 1.77m |
In November 2025, AIMO GmbH achieved ISO/IEC 27001:2022 certification for its information security management system, covering the SaaS platform behind our consumer health app. The certificate is valid through November 2028 and underpins our relationships with health-insurance partners, for whom data security is a precondition for doing business.
Net sales at AIMO GmbH were €216,958 in 2025, shaped by a change in how statutory health-insurance partners (Krankenkassen) reimburse AIMO: from 2025 onward, payment is tied to completed courses rather than user registrations — a materially stricter criterion. Quarterly payments dipped through 2025 during this conversion but have already stabilised in 2026. The Board’s current budget targets net sales of approximately €455,000 for the full year. AIMO GmbH also expects an Investitionszulage instalment of €120,000 in 2026.
AIMO Group AB reported a net result of –SEK 2,443,848 for 2025 (2024: –SEK 70,765). This is almost entirely a one-off accounting clean-up: the Group’s dormant Danish subsidiary AIMO ApS was fully dissolved — intellectual property transferred to AIMO GmbH, intercompany receivables waived, entity struck off the Danish register. The resulting write-offs of SEK 2,435,776 generate a Swedish tax loss carryforward of approximately SEK 2,374,946. Group structure is now simply AIMO Group AB as sole shareholder of AIMO GmbH.
Three things drive our plan: more statutory health-insurance partners, stronger retention from the redesigned app, and the new ZPP course concept launching Q3 2026. The Board’s internal planning targets a sustained growth path with net result turning solidly positive from 2027:
| 2025A | 2026E | 2027E | 2028E | 2029E | |
|---|---|---|---|---|---|
| Net sales | € 299,000 | € 455,000 | € 636,000 | € 1,092,000 | € 3,623,000 |
| Net result | € 44,000 | € 88,000 | € 198,000 | € 505,000 | € 2,769,000 |
These figures reflect internal management planning assumptions as of mid-2026; they are not audited and are not a guarantee of future results.
The Board of AIMO Group AB comprises Danny Dressler (Chairman), Steffen Haack, and Eduard Rall. We thank both Board members and our growing AIMO GmbH team for their contributions over the past year.
On behalf of the Board, thank you for your continued trust and support as shareholders.